Replimune Group, Inc. REPL · Stock Open Replimune Group, Inc. in new tab
Replimune Group, Inc. Analysis (REPL)
Is Replimune Group, Inc. a good investment? Replimune Group, Inc. (REPL) is currently trading at 9.70 USD. Market analysts have a consensus price target of 10.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: Replimune Group, Inc. is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is -1.15.
Investor FAQ
Does Replimune Group, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Replimune Group, Inc.?
Replimune Group, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -3.38.
Company Profile
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4. The company was founded in 2015 and is headquartered in Woburn, Massachusetts.
Community Discussion